We are in a golden era for human health, driven by an unprecedented acceleration in our understanding of human biology. This opens substantial economic opportunity to invest in the future of medicine while addressing major unmet needs. Yet, few experimental drugs become successful therapies, and each validated biological target sparks intense competition to be first or best in class. Our mission is to shoulder that complexity and selectively back the potential winners.